Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
| Status: | Recruiting |
|---|---|
| Conditions: | Endocrine |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | Any - 21 |
| Updated: | 12/22/2017 |
| Start Date: | September 18, 2017 |
| End Date: | December 31, 2017 |
| Contact: | Dat Nguyen, PharmD |
| Email: | dnguyen@corcept.com |
| Phone: | 650-688-2843 |
This retrospective, multi-center, chart review study will collect patient data from medical
charts of pediatric patients who have been treated with Korlym for Cushing's syndrome.
charts of pediatric patients who have been treated with Korlym for Cushing's syndrome.
This retrospective chart review study seeks to collect data from pediatric patients treated
with Korlym (mifepristone) to help provide clinicians with some insight on the potential role
of mifepristone in the treatment of pediatric patients with Cushing syndrome.
Only sites that have been identified to have patients appropriate for this protocol will be
invited to participate and contribute data on their patients
Data to be collected from a retrospective chart review will include:
- Patient demographics
- Medical history
- Pre and post treatment clinical assessments and laboratory results
- Radiologic findings (if available)
- Adverse events
Data will be collected for all follow-up visits, up until the most recent encounter prior to
IRB approval.
with Korlym (mifepristone) to help provide clinicians with some insight on the potential role
of mifepristone in the treatment of pediatric patients with Cushing syndrome.
Only sites that have been identified to have patients appropriate for this protocol will be
invited to participate and contribute data on their patients
Data to be collected from a retrospective chart review will include:
- Patient demographics
- Medical history
- Pre and post treatment clinical assessments and laboratory results
- Radiologic findings (if available)
- Adverse events
Data will be collected for all follow-up visits, up until the most recent encounter prior to
IRB approval.
Inclusion Criteria:
- Pediatrics (age≤21 years) at time Korlym initiation
- Considered to have a diagnosis of endogenous Cushing's syndrome by the healthcare
provider
- Received at least one dose of Korlym
- Availability of pre-treatment (baseline) and follow-up data
Exclusion Criteria:
We found this trial at
1
site
Click here to add this to my saved trials
